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Dear Dr. Menown,
I am pleased to report that we have received
considerable interest since the publication of
our article (Ruilope L, Schaefer A. The fixed-dose
combination of olmesartan/amlodipine was
superior in central aortic blood pressure
reduction compared with perindopril/
amlodipine: a randomized, double-blind trial
in patients with hypertension. Adv Ther.
2013;30:1086–99 [1]) last December. The
results confirmed the effects of combined
renin angiotensin system and calcium channel
blockade on lowering central blood pressure.
Furthermore, it extended these findings by
showing that the angiotensin II receptor
blocker olmesartan medoxomil could produce
similar changes in central blood pressure when
combined with a calcium channel blocker.
One enquiry concerned the levels of baseline
blood pressure in the treatment groups
described in the report. We are happy to
provide these baseline values here, but feel
that it is advisable to first remind readers of
the context in which these data should be
viewed. The use of a 4-week run-in period before
the start of double-blind treatment meant that
all patients had been treated with amlodipine
for at least 4 weeks (Table 1 footnotes). Some
patients would have received amlodipine 5 mg
for the first 2 weeks of the run-in period and
then been uptitrated to amlodipine 10 mg for
the final 2 weeks. Furthermore, some patients
had also received other antihypertensive agents
for up to 2 weeks before the start of double-
blind treatment and some had received
amlodipine 10 mg for more than 2 weeks.
Amlodipine is an effective antihypertensive
agent and even though patients entered
double-blind treatment only if their blood
pressure control was inadequate, the
treatments used prior to double-blind
treatment would have already produced
significant reductions in blood pressure. This
should be remembered when looking at the
baseline data (Table 1). Also, as specified in the
study protocol, the per protocol set was used to
assess changes in the primary variable (central
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systolic blood pressure) and the full analysis set
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Per protocol set n = 198 n = 192 n = 390
Central SBP, mmHg 135.3 (11.57) 135.2 (10.89) 135.3 (11.22)
Full analysis set n = 221 n = 221 n = 442
Seated SBP, mmHg 148.5 (10.30) 148.9 (11.93) 148.7 (11.13)
24-h ambulatory SBP, mmHg 134.8 (11.62) 133.3 (11.28) 134.0 (11.46)
Daytime ambulatory SBP, mmHg 138.3 (12.10) 137.1 (11.58) 137.7 (11.84)
Night-time ambulatory SBP, mmHg 126.9 (12.72) 125.0 (13.02) 125.9 (12.89)
Central DBP, mmHg 86.8 (9.30) 87.3 (9.68) 87.1 (9.48)
Seated DBP, mmHg 85.8 (8.92) 86.1 (9.43) 86.0 (9.17)
24-h ambulatory DBP, mmHg 79.2 (8.76) 79.2 (8.36) 79.2 (8.55)
Daytime ambulatory DBP, mmHg 82.0 (9.31) 82.1 (8.44) 82.0 (8.88)
Night-time ambulatory DBP, mmHg 73.1 (8.76) 73.1 (9.52) 73.1 (9.14)
Values are mean (standard deviation)
Before starting double-blind treatment patients entered a 4-week run in, unless they had been receiving amlodipine 10 mg as
monotherapy before the study (in which case they entered double-blind treatment directly). Patients who had been receiving
drug treatment before the study continued with their former medication (except for calcium channel blockers) during the
ﬁrst 2 weeks of the run in and also received amlodipine 5 mg once daily. During the ﬁnal 2 weeks of the run in, all former
medications were withdrawn and patients received amlodipine 10 mg as their only treatment. Patients entered double-blind
treatment if their seated systolic blood pressure/diastolic blood pressure was C140/90 mmHg (C130/80 mmHg for diabetes
or CKD). For a description of the per protocol and full analysis sets, please see Ruilope and Schaefer [1]
AML amlodipine, DBP diastolic blood pressure, OLM olmesartan, PER perindopril, SBP systolic blood pressure
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